AU4064285A - Sustained release pharmaceutical capsules - Google Patents
Sustained release pharmaceutical capsulesInfo
- Publication number
- AU4064285A AU4064285A AU40642/85A AU4064285A AU4064285A AU 4064285 A AU4064285 A AU 4064285A AU 40642/85 A AU40642/85 A AU 40642/85A AU 4064285 A AU4064285 A AU 4064285A AU 4064285 A AU4064285 A AU 4064285A
- Authority
- AU
- Australia
- Prior art keywords
- percent
- capsule
- hydroxypropylmethylcellulose
- sustained
- contents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002775 capsule Substances 0.000 title claims description 44
- 238000013268 sustained release Methods 0.000 title claims description 22
- 239000012730 sustained-release form Substances 0.000 title claims description 22
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 35
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 35
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 30
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 23
- -1 hydroxypropoxyl Chemical group 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 12
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000007903 gelatin capsule Substances 0.000 claims description 8
- 229960004535 oxazepam Drugs 0.000 claims description 8
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 7
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 6
- 229960004391 lorazepam Drugs 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- UVTLONZTPXCUPU-ZNMIVQPWSA-N ciramadol Chemical compound C([C@@H]1[C@@H](N(C)C)C=2C=C(O)C=CC=2)CCC[C@H]1O UVTLONZTPXCUPU-ZNMIVQPWSA-N 0.000 claims description 5
- 229950007653 ciramadol Drugs 0.000 claims description 5
- 229960004553 guanabenz Drugs 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241000237519 Bivalvia Species 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 239000007891 compressed tablet Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960003050 guanabenz acetate Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013269 sustained drug release Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methylideneamino]guanidine Chemical compound NC(N)=NN=CC1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-UHFFFAOYSA-N 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940095523 buccal product Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59173884A | 1984-03-21 | 1984-03-21 | |
| US591738 | 1984-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU4064285A true AU4064285A (en) | 1985-10-11 |
Family
ID=24367713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU40642/85A Abandoned AU4064285A (en) | 1984-03-21 | 1985-02-22 | Sustained release pharmaceutical capsules |
Country Status (13)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2176999B (en) * | 1985-06-22 | 1989-07-12 | Stanley Stewart Davis | Sustained release medicament |
| NL194822C (nl) * | 1985-10-01 | 2003-04-03 | Novartis Ag | Preparaat voor orale toediening met geregelde afgifte en werkwijze voor de bereiding ervan. |
| SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
| GB8624213D0 (en) * | 1986-10-09 | 1986-11-12 | Sandoz Canada Inc | Sustained release pharmaceutical compositions |
| GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| YU47044B (sh) * | 1987-03-11 | 1994-12-28 | LEK TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV n.sol.o. | Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase |
| FR2618073B1 (fr) * | 1987-07-16 | 1990-09-07 | Pf Medicament | Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation |
| IT1222414B (it) * | 1987-07-31 | 1990-09-05 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico |
| US5232704A (en) * | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
| US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| KR100321489B1 (ko) | 1996-07-08 | 2002-10-09 | 에드워드 멘델 컴파니 인코포레이티드 | 고용량의불용성약물용서방성매트릭스 |
| US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| US8912192B2 (en) | 2010-02-12 | 2014-12-16 | Taisho Pharmaceutical Co., Ltd | Extended release preparation |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| PE20151431A1 (es) * | 2013-01-09 | 2015-09-23 | Edgemont Pharmaceuticals Llc | Formulaciones de lorazepam de liberacion controlada |
| KR20210052281A (ko) * | 2019-10-29 | 2021-05-10 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 캡슐 충전용 조성물 및 이것을 사용한 캡슐 제제의 제조 방법 그리고 캡슐 제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
| US3427378A (en) * | 1965-02-12 | 1969-02-11 | American Cyanamid Co | Sustained release encapsulated formula |
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| FR2525474A1 (fr) * | 1982-04-26 | 1983-10-28 | Roussel Uclaf | Nouvelle forme pharmaceutique orale de clometacine |
| CH666406A5 (de) * | 1984-02-29 | 1988-07-29 | Sandoz Ag | Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten. |
-
1985
- 1985-02-22 WO PCT/US1985/000300 patent/WO1985004100A1/en active Application Filing
- 1985-02-22 AU AU40642/85A patent/AU4064285A/en not_active Abandoned
- 1985-02-22 KR KR1019850700316A patent/KR850700212A/ko not_active Withdrawn
- 1985-02-22 JP JP60500994A patent/JPS61501511A/ja active Pending
- 1985-02-22 FI FI854573A patent/FI854573A7/fi not_active Application Discontinuation
- 1985-03-12 GR GR850625A patent/GR850625B/el unknown
- 1985-03-13 ZA ZA851891A patent/ZA851891B/xx unknown
- 1985-03-14 EP EP85301756A patent/EP0156592A3/en not_active Withdrawn
- 1985-03-14 GB GB08506656A patent/GB2157169A/en not_active Withdrawn
- 1985-03-18 PT PT80124A patent/PT80124B/pt unknown
- 1985-03-19 HU HU851011A patent/HUT38262A/hu unknown
- 1985-03-20 ES ES541394A patent/ES8700935A1/es not_active Expired
- 1985-11-15 DK DK529885A patent/DK529885D0/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUT38262A (en) | 1986-05-28 |
| FI854573L (fi) | 1985-11-20 |
| ZA851891B (en) | 1986-10-29 |
| FI854573A0 (fi) | 1985-11-20 |
| ES8700935A1 (es) | 1986-11-16 |
| PT80124B (en) | 1986-11-14 |
| KR850700212A (ko) | 1985-12-26 |
| FI854573A7 (fi) | 1985-11-20 |
| GB8506656D0 (en) | 1985-04-17 |
| ES541394A0 (es) | 1986-11-16 |
| GB2157169A (en) | 1985-10-23 |
| EP0156592A2 (en) | 1985-10-02 |
| GR850625B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-06-17 |
| EP0156592A3 (en) | 1987-03-11 |
| DK529885A (da) | 1985-11-15 |
| PT80124A (en) | 1985-04-01 |
| JPS61501511A (ja) | 1986-07-24 |
| DK529885D0 (da) | 1985-11-15 |
| WO1985004100A1 (en) | 1985-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4064285A (en) | Sustained release pharmaceutical capsules | |
| US6372252B1 (en) | Guaifenesin sustained release formulation and tablets | |
| AU613663B2 (en) | Sustained release etodolac | |
| US7985421B2 (en) | Sustained release formulations of guaifenesin and additional drug ingredients | |
| FI93608C (fi) | Menetelmä ksantaanikumia sisältävän, kiinteän lääkevalmisteen valmistamiseksi | |
| EP0632720B1 (en) | Hydroxyethylcellulose-based sustained-release oral drug dosage froms | |
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| AU781718B2 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
| AU2001255680A1 (en) | Guaifenesin sustained release formulation and tablets | |
| NZ550648A (en) | Pharmaceutical compositions comprising an amphiphilic starch | |
| JP2931409B2 (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| AU729437B2 (en) | Cefadroxil monohydrate tablet formulation | |
| GB2105590A (en) | Flotable controlled release preparations | |
| MXPA04010225A (es) | Liberacion sostenida de la combinacion de guaifenesina con farmacos. | |
| US20070178155A1 (en) | Preparation for gastric buoyant sustained drug release dosage form | |
| CN1172429A (zh) | 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系 | |
| HK1052651B (en) | Guaifenesin sustained release formulation and tablets | |
| HK1115549A (en) | Guaifenesin sustained release formulation and tablets |